Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram Blood-Brain Barrier Permeability and Sleep by ABCB1 Genotype
DRKS00006241Phase 4Completed
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of escitalopram (2 arms), sponsored by Max Planck Institute of Psychiatry. Primary endpoints: Minimal REM sleep suppressing dose of escitalopram and Effect of escitalopram on sleep EEG by ABCB1 genotype. Started Nov 2014; status: completed.
02
Drugs
escitalopram
Beyond the preview
Go deeper on DRKS00006241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00006241.